Positive EMA/CHMP opinion for GlaxoSmithKline’s diabetes drug Eperzan

24 January 2014

Among a batch of positive opinions issued today by the European Medicines Agency’ s Committee for Medicinal Products for Human Use (CHMP), there was good news for UK pharma giant GlaxoSmithKline (LSE: GSK) relating to Eperzan (albiglutide).

The CHMP recommending marketing authorization for albiglutide, proposed as a once-weekly treatment to improve glycemic control in adult patients with type 2 diabetes mellitus:

as monotherapy, when diet and exercise alone do not provide adequate glycemic control in patients for whom the use of metformin is considered inappropriate due to contraindications or intolerance; and
as add-on combination therapy, in combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycemic control.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK